Phase III cSSSI

Related by string. * phases . Phases . phase . PHASE . PHASES : Phase III clinical trials . Phase III trials . Phase 2b clinical . pivotal Phase III . ongoing Phase 1b / Iii . iii . IIIs . IIID . IIi : Star Wars Episode III . Phase III clinical . Guitar Hero III . Tha Carter III . Episode III Revenge / cSSSIs : Skin Structure Infections cSSSI . structure infections cSSSI . structure infections cSSSIs . cSSSI * *

Related by context. Frequent words. (Click for all words.) 51 elotuzumab 50 limiting toxicity 50 Adverse reactions 49 treatment emergent adverse 48 Fibrillex TM 48 hypercalcemia 48 GSK# [001] 48 discontinuations due 48 Anturol 47 QT prolongation 47 events SAEs 47 Diamyd R 46 nasopharyngitis 46 renal toxicity 46 diarrhea nausea vomiting 46 vernakalant oral 46 Bicifadine 45 angioedema 45 ISTODAX 45 isavuconazole 45 Diamyd ® 45 infusion reactions 45 chemotherapy induced neutropenia 45 Lactic acidosis 45 hepatotoxicity 45 leukopenia 45 patients receiving ERBITUX 44 nausea diarrhea 44 adverse reactions 44 lacosamide 44 approvability 44 adverse 44 Adverse events 44 tumor lysis syndrome 43 forodesine 43 radiation dermatitis 43 teratogenic 43 INTEGRILIN 43 events AEs 43 TRISENOX 43 FavId 43 Allergic reactions 43 hypersensitivity reactions 43 unknown etiology 43 mucositis 43 discontinuations 42 lymphopenia 42 GEMZAR 42 xxii 42 laboratory abnormalities 42 thromboembolic 42 Exelbine 42 Thrombocytopenia 42 Secondary endpoints include 42 neuropsychiatric symptoms 41 NUEDEXTA 41 hypomagnesemia 41 Secondary endpoints 41 hyperbilirubinemia 41 venous thromboembolic events 41 thromboembolic events 41 cardiac toxicity 41 bone marrow suppression 41 TOCOSOL Paclitaxel 40 deforolimus 40 Secondary endpoints included 40 lactic acidosis 40 metabolic acidosis 40 aprepitant 40 lumiracoxib 40 REMICADE ® 40 hypocalcemia 39 hypoglycemic events 39 NEUMUNE 39 febrile neutropenia 39 impaired renal 39 thrombocytopenia 39 PROPEL trial 39 sensory neuropathy 39 pneumonitis 39 atacicept 39 toxicities 39 Neutropenia 39 Urocidin 39 omecamtiv mecarbil 38 COPD exacerbations 38 Adverse Events 38 AVANDIA 38 Complete Response 38 oral mucosa 38 anaphylactic reactions 38 cerebrovascular events 38 peripheral edema 38 serotonin syndrome 38 TYSABRI treated 37 alagebrium 37 conducing 37 regulatory authorizations 37 cSSSI 37 Observational studies 37 arthralgia

Back to home page